AWARI	D/CONTRACT	1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700)					RATING	PAGE OF	PAGES 21		
 CONTRACT (W911SR203000 	(Proc. Inst. Ident.) NO.	3. EFFECTIVE DATE 20200701 4.1			4. REQUIS 0011506628-00	EQUISITION/PURCHASE REQUEST/PROJECT NO. 06628-0002					
EDGEWOOD CONTR 8456 BRIGADE STREE BLDG E4215	CMD-APG W911SR ACTING DIVISION	W911SR		DCMA BLDG.	SPR NG 93	ST EREI F ELD - S: 07806-500		than Item 5)	COD	S3101A	
7. NAME AND A BECTON, DICK NSON 1 BECTON DR FRANKL N LAKES NJ		TOR (No., street, city,	, county, state a	and zip co	ode)	ŏ	5	DISCOUNT Net 30 Days	BORIGIN [X] C FOR PROMPT PAYMEN IVOICES 1 otherwise specified)	OTHER (See beld) IT ITEM Section	
CODE 06531		FACILITY CODE						HOWN IN:			
11. SHIP TO/MARK FOR CODE W56XNH BIOMEDICAL ADVANCED RESEARCH DEVELOPMENT (b) (6) ROOM 23EU7 O'NEILL HOUSE OFFICE BUILD NG WASHINGTON DC 20515				12. PAYMENT WILL BE MADE BY DFAS-COLUMBUS CENTER NORTH ENTITLEMENT OPERATIONS P.O. BOX 182266 COLUMBUS OH 43218-2266							
13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION: [] 10 U.S.C. 2304(c)() [] 41 U.S.C. 253(c)()				14. ACCOUNTING AND APPROPRIATION DATA See Schedule							
15A. ITEM NO.		PLIES SERVICES		15C.	QUAN	TITY	15D. UNI	Г	15E. UNIT PRICE	15F. AMO	UNT
	SEE S	CHEDULE									
						15G	. TO TAL A	MOUNTO	FCONTRACT	\$42,30	3,230.00
(X) SEC.	DESCRIPTIO		PAGE(S)					-	DESCRIPTION		PAGE(S
(A) SEC.	PARTI - THE SCH		PAGE(S)	(A)	SEC.		PAR		TRACTCLAUSES		PAGE(5
	CITATION/ CONTRACT I		1	Х			RACT CLAU	SES			10 - 21
	LIES OR SERVICES AND RIPTION/ SPECS./ WORK		2				LIST OF DO F ATT ACH!		S, EXHIBITS AND O	THER ATTAC	Η.
	AGING AND MARKING	SIAIEMENI			J				IONS AND INSTRU	CTIONS	
X E INSPECTION AND ACCEPTANCE 3				K				TCATIONS AND			
	VERIES OR PERFORMAN		4	\vdash			STATEME				
	<u>'RACT ADMINISTRATIO</u> IAL CONTRACT REQUIF		5 6 - 9	\vdash			ATION FAC		CES TO OFFERORS		
	ACTING OFFICER WILL COM		_	NEGO	_					AS APPLICABLE	
17 [X] CONTRACTOR'S NEGOTIATED AGREEMENT Contractor is required to sign this document and return1 copies to issuing office) Contractor agrees to furnish and deliver all items or perform all the services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein. The rights and obligations of the parties to this contract shall be subject to and governed by the following documents: (a) this award/contract, (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, as are attached or incorporated by reference herein. (Attachments are listed herein) 19A. NAME AND TITLE OF SIGNER (Type or print)				18 [] SEALED-BID AWARD (Contractor is not required to sign this document) Your bid on Solicitation Number including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the terms listed above and on any continuation sheets. This award consummates the contract which consists of the following documents: (a) the Government's solicitation and your bid, and (b) this award/contract. No further contractual document is necessary (Block 18 should be checked only when awarding a sealed-bid contract) 20A. NAME OF CONTRACTING OFFICER [
19B. NAME OF COINT RACTOR Becto I, Dickinson, and Company (b) (6) (Signature of person author zed to sign) 19C. DATE SIGNED 7/1/2020			20B. BY_	UNIT	ED STA	(Signature of	ERICA (b) (6) Contracting Office	cer)	20C. DATE SI 2020070		

Previous edition is NOT usable

ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0001 Job \$42,303,230.00 NTE

TECHNOLOGY INVESTMENT AGREEMENT

COST

Technology Investment Agreement (TIA) for Expanding Domestic Production of Needles and Syringes in accordance with (IAW) Recipient Proposal dated 25 June 2020.

FOB: Destination PSC CD: 6515

ESTIMATED COST \$42,303,230.00

ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 000101 \$0.00

Funding for CLIN 0001

COST

This line item is created for funding purposes only. PURCHASE REQUEST NUMBER: 0011506628-0002

ESTIMATED COST \$0.00

ACRN AA \$42,303,230.00

CIN: GFEBS001150662800001

INSPECTION AND ACCEPTANCE TERMS

Supplies/services will be inspected/accepted at:

CLIN INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
0001 Destination	Government	Destination	Government
000101 N/A	N/A	N/A	N/A

Section F - Deliveries or Performance

DELIVERY INFORMATION

CLIN	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC / CAGE
0001	POP 01-JUL-2020 TO 30-JUN-2030	N/A	BIOMEDICAL ADVANCED RESEARCH DEVELOPMENT JOSEPH FIGLIO ROOM 23E07 O'NEILL HOUSE OFFICE BUILDING WASHINGTON DC 20515 FOB: Destination	W56XNH
000101	N/A	N/A	N/A	N/A

Section G - Contract Administration Data

ACCOUNTING AND APPROPRIATION DATA

AA: 0212020202120400000664643255 S.0074658.5.1 6100.9000021001

COST CODE: A5XAH AMOUNT: \$42,303,230.00

ACRN CLIN/SLIN CIN AMOUNT

AA 000101 GFEBS001150662800001 \$42,303,230.00

SECTION H

H.1 Key Personnel

H.1.1 Pursuant to HHSAR 352.237-75 (Dec 2015), Key Personnel, any key personnel specified in this agreement are considered to be essential to work performance. At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or agreements the Contractor shall notify the Agreements Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement's skills, experience, and credentials meet or exceed the requirements of the agreement (including, when applicable, Human Subjects Testing requirements). If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Agreements Officer. The agreement will be modified to add or delete key personnel as necessary to reflect the agreement of the parties. The following individuals are determined to be key personnel:

H.1.2 Substitution of Key Personnel

- H.1.2.1 The Contractor agrees to assign to the agreement those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the agreement. No substitutions shall be made except in accordance with this clause.
- H.1.2.2 All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the Agreements Officer to approve or disapprove the proposed substitution. All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced. The Agreements Officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.
- H.1.2.3 The contractor further agrees to include the substance of this clause in any subcontract, which may be awarded under this agreement.

H.2 Disclosure of Information:

- H.2.1 Performance under this agreement may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this agreement, except authorized by Government personnel or upon written approval of the CO. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this agreement, or any information at all regarding this agency.
- H.2.2 Consistent with HHS Directive 1139, the Contractor shall comply with HHS requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the HHS's rules. Unauthorized disclosure may result in termination of the agreement, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractor's employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity's security or interrupt the continuity of its operations.
- H.2.3 No information related to data obtained under this agreement shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for

submission to any government entity' for submission to any securities exchange on which the Contractor's (or its parent corporation's) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions.

H.2.4 Publication and Publicity

- H.2.4.1 The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this agreement without written notice in advance to the Government, for additional information see HHSAR 352.227-70. Publications and Publicity (Dec 2015).
- (a) Unless otherwise specified in this agreement, the contractor may publish the results of its work under this agreement. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.
- (b) Unless authorized in writing by the AO, the contractor shall not display the HHS logo including Operating Division or Staff Division logos on any publications.
- (c) The contractor shall not reference the products(s) or services(s) awarded under this agreement in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies HHS approval or endorsement of the product(s) or service(s) provided.
- (d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this agreement in any media by including an acknowledgement substantially as follows:

"This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Agreement No. W911SR2030004."

H.3 Confidentiality of Information

- a. Confidential information, as used in this article, means information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.
- b. The Agreements Officer and the Contractor may, by mutual consent, identify elsewhere in this agreement specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Agreements Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the agreement. Failure to agree will be settled pursuant to the "Disputes" clause.
- c. If it is established elsewhere in this agreement that information to be utilized under this agreement, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.
- d. Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.
- e. Whenever the Contractor is uncertain with regard to the proper handling of material under the agreement, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Agreements Officer prior to any release, disclosure, dissemination, or publication.
- f. Agreements Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.

g. The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.

All above requirements MUST be passed to all Sub-contractors.

H.4 Organizational Conflicts of Interest:

- H.4.1 Performance under this agreement may create an actual or potential organizational conflict of interest such as are contemplated by FAR Part 9.505-General Rules. The Contractor shall not engage in any other contractual or other activities which could create an organizational conflict of interest (OCI). This provision shall apply to the prime Contractor and all sub-Contractors. This provision shall have effect throughout the period of performance of this agreement, any extensions thereto by change order or supplemental agreement, and for two (2) years thereafter. The Government may pursue such remedies as may be permitted by law or this agreement, upon determination that an OCI has occurred.
- H.4.2 The work performed under this agreement may create a significant potential for certain conflicts of interest, as set forth in FAR Parts 9.505-1, 9.505-2, 9.505-3, and 9.505-4. It is the intention of the parties hereto to prevent both the potential for bias in connection with the Contractor's performance of this agreement, as well as the creation of any unfair competitive advantage as a result of knowledge gained through access to any non-public data or third party proprietary information.
- H.4.3 The Contractor shall notify the Agreements Officer immediately whenever it becomes aware that such access or participation may result in any actual or potential OCI. Furthermore, the Contractor shall promptly submit a plan to the Agreements Officer to either avoid or mitigate any such OCI. The Agreements Officer will have sole discretion in accepting the Contractor's mitigation plan. In the event the Agreements Officer unilaterally determines that any such OCI cannot be satisfactorily avoided or mitigated, other remedies may be taken to prohibit the Contractor from participating in agreement requirements related to OCI.
- H.4.4 Whenever performance of this agreement provides access to another Contractor's proprietary information, the Contractor shall:
- (1) enter into a written agreement with the other entities involved, as appropriate, in order to protect such proprietary information from unauthorized use or disclosure for as long as it remains proprietary; and refrain from using such proprietary information other than as agreed to, for example to provide assistance during technical evaluation of other Contractors' offers or products under this agreement. An executed copy of all proprietary information agreements by individual personnel or on a corporate basis shall be furnished to the CO within fifteen (15) calendar days of execution.

H.5 Operations Security (OPSEC)

- H.5.1 The contractor shall develop and submit an OPSEC Standing Operating Procedure (SOP)/Plan within 30 calendar days of agreement award, to be reviewed and approved by the Government OPSEC lead for this effort. The final OPSEC plan, must address the Government's identified Critical Information List (CIL)
 - a) All contractors supporting this effort must complete OPSEC Computer Based Training (CBT) that can be accessed via the (Insert applicable website here).

H.6 Security

- H.6.1 The contractor shall develop a comprehensive security plan that complies with the attached BARDA Security Requirements (Attachment C). The Recipient's plan shall be delivered to the Government within 30 days of award. The contractor shall also ensure all subcontractors, consultants, researchers, etc. performing work on behalf of this effort, comply with all BARDA security requirements and prime contractor security plans.
 - a) ASPR will review in detail and submit comments within ten (10) business days to the Agreements Officer (AO) to be forwarded to the Contractor. The Contractor shall review the Draft Security Plan comments,

- and, submit a Final Security Plan to the U.S. Government within thirty (10) calendar days after receipt of the comments.
- b) The Security Plan shall include a timeline for compliance of all the required security measures outlined by BARDA.
- c) Upon completion of initiating all security measures, the Contractor shall supply to the Agreements Officer a letter certifying compliance to the elements outlined in the Final Security Plan.

TERMS AND CONDITIONS

TECHNOLOGY INVESTMENT AGREEMENT

between

Becton, Dickinson and Company

and

Department of Defense,
U.S. Army Contracting Command – Aberdeen Proving Ground,
Natick Contracting Division & Edgewood Contracting Division
(ACC-APG, NCD & ECD)

on behalf of

Biomedical Advanced Research and Development Authority (BARDA)

for

Expanding Domestic Production of Needles & Syringes

Agreement No: W911SR2030001

Total Amount of Government Funding for the Agreement: \$42,303,230.00

Total Cost Share for the Agreement: USG 60% --- BD 40% Total Estimated Value of the Agreement: \$70,505,383.00

Effective Date: 1 July 2020

Term of Agreement: Ten (10) Years after Date of Award

TECHNOLOGY INVESTMENT AGREEMENT TERMS AND CONDITIONS

ARTICLES

- 1. Scope of Agreement
- 2. Term of Agreement
- 3. Order of Precedence
- 4. Program/Administrative Management
- 5. Financial Management & Payment
- 6. Accounting & Audit
- 7. Purchasing & Title
- 8. Cost Sharing
- 9. Government Preference
- 10. Records Retention & Government Access
- 11. Intellectual Property & Patent Rights
- 12. Data Rights
- 13. FDA Regulatory Requirements
- 14. Termination
- 15. Disputes
- 16. Reports & Distribution
- 17. Modification
- 18. Miscellaneous



RECITALS

This Agreement is entered into between the United States of America, Department of Defense, represented by ACC-APG, NCD & ECD ("Government") and Becton, Dickinson and Company, ("Recipient"), collectively referred to as the "Parties," pursuant to and under the statutory authority at 10 U.S.C. §2371 and/or 10 U.S.C. §2358.

The Recipient, a for-profit firm, submitted a basic, applied, or advanced research proposal to the Government in response to the publicly disseminated Medical Countermeasures System (MCS) Broad Agency Announcement (BAA) 17-01. The proposal was identified within the MCS BAA scope of: Advanced Development & Manufacturing Capabilities (ADMC), to develop a national capability and capacity to develop and produce medical countermeasures rapidly to counter known or unknown chemical, biological, radioactive, and nuclear (CBRN) threats, including novel and previously unrecognized, naturally- occurring emerging infectious diseases such as the COVID-19 virus. The specific MCS BAA Area of Interest is Mission Area 1, Medical Biological Prophylaxis.

The Government awards this Technology Investment Agreement (TIA) to fund the Recipient proposal subject to the following terms and conditions and other statutory requirements. The Parties desire to enter into this Agreement to establish said terms and conditions under which they plan to carry out the research and other activities as described below.

THEREFORE, THE PARTIES AGREE:

1. Scope of Agreement

- 1.1 Governing Authority. This Technology Investment Agreement (TIA) is an assistance transaction other than a grant or cooperative agreement and is awarded pursuant to 10 USC §2371 and/or 10 USC §2358, as applicable, as implemented by 32 Code of Federal Regulations (CFR) Part 37, and Parts 22 and 34 where specifically referenced. The following are also incorporated in full: Definitions at Subpart J of 32 CFR Part 37; National Policies at Appendix B, 32 CFR Part 22; Audits at Appendix C of 32 CFR Part 37. This TIA is subject good manufacturing practices (cGMPS) at 21 CFR 210 and 211, as applicable. The Federal Acquisition Regulation (FAR), Defense Federal Acquisition Regulation Supplement (DFARS), DoD Grant and Agreement Regulations (DoDGARs), or other regulatory and statutory requirements apply as specifically referenced herein. If this instrument is awarded under the authority at 10 USC §2358, the Bayh-Dole Act, 35 U.S.C. §§ 200-212 applies, as applicable.
- 1.2 Principal Purpose. The Government and the Recipient agree that the principal purpose of this Agreement is for Government investment into the development/expansion of Recipient's manufacturing capacity for hypodermic safety needles and corresponding syringes in response to the worldwide Coronavirus (COVID-19) global pandemic as described in the Recipient's Final Proposal, hereinafter, the "Plan" or "Project". This effort shall be carried out as set forth in the Recipient's Plan and subsequent revisions, which are hereby incorporated in their entirety. This Agreement is not intended to be, nor shall it be construed as, by implication or otherwise, a partnership, a corporation, or other business organization.
- **2. Term of Agreement.** This Agreement shall commence upon the effective date listed on page 1, after execution of the Agreement by both parties, for a period of 10 years, the "term" of the Agreement or "Period of Performance." *Period of performance* means the time during which a recipient or sub-recipient may incur new obligations to carry out the work authorized under an award or sub-award, respectively.
- **3. Order of Precedence**. This Agreement is subject to the laws and regulations of the United States. In the event of a conflict or inconsistency in the terms and conditions or attachments specified in this Agreement, the conflict or inconsistency shall be resolved according to the following order of precedence: (a) the Federal statute authorizing this award, or any other Federal statutes directly affecting performance of this Agreement, including attachments where applicable; (b) Federal regulations specifically references; (c) the terms and conditions contained within the Agreement, including any documents incorporated; (d) programmatic requirements.

4. Program/Administrative Management

4.1 Program Management. The Recipient has full responsibility for the project/activity supported by this Agreement,


in accordance with the Recipient's proposal and proposal revisions/appendices, and the terms and conditions specified in this Agreement. The Government will have continuous and/or substantial involvement with the Recipient pursuant to a Collaboration Plan as incorporated. The Recipient must consult the Program Office/Technical Representative through the Agreements Officer before deviating from the objectives or overall program of the research originally proposed. Non-compliance with any award provision of this clause may result in the withholding of funds and or the termination of the award.

4.2 Government Representatives:



4.3 Recipients Representatives





5. Financial Management & Payment

5.1 Expenditure-Based. This Agreement is an expenditure type TIA as described in 32 CFR §37.1285. *Expenditure* is defined in 32 CFR §37.1290. The charges may be reported on a cash or accrual basis, as long as the methodology is disclosed and is consistently applied. In accordance with 32 CFR 37.300(a): "For an expenditure-based TIA, the amounts of interim payments or the total amount ultimately paid to the Recipient are based on the amounts the Recipient expends on project costs. If a Recipient completes the project specified at the time of award before it expends all of the agreed-upon Federal funding and Recipient cost sharing, the Federal Government may recover its share of the unexpended balance of funds or, by mutual agreement with the Recipient, amend the agreement to expand the scope of the research project. An expenditure-based TIA therefore is analogous to a cost-type procurement contract or grant."

Payments shall be made on a monthly basis for expenditures incurred up to the agreed upon project ceiling & Government investment funding amount, for the duration of the Period of Performance.

- 5.2 Obligation In no case shall the Government's financial obligation exceed the amount obligated on this Agreement or by amendment to the Agreement. The Government is not obligated to reimburse the Recipient for expenditures in excess of the amount of obligated funds allotted by the Government.
- 5.3 Wide Area Workflow. The following guidance is provided for invoicing processed under this Agreement through WAWF:
- 5.3.1. Acceptance within the WAWF system shall be performed by the AGO upon receipt of a confirmation email, or other form of transmittal, from the BARDA PM.
- 5.3.2. The Recipient shall send an email notice to the BARDA PM and upload the BARDA PM approval as an attachment upon submission of an invoice in WAWF (this can be done from within WAWF).
- 5.3.3. Payments shall be made by the Defense Finance and Accounting Services (DFAS) office indicated below within thirty (30) calendar days of an accepted invoice in WAWF:
- 5.3.4. WAWF Provision:

(a) Definitions. As used in this clause--

Department of Defense Activity Address Code (DoDAAC) is a six position code that uniquely identifies a unit, activity, or organization.

Document type means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).

Local processing office (LPO) is the office responsible for payment certification when payment certification is done external to the entitlement system.

- (b) Electronic invoicing. The WAWF system is the method to electronically process vendor payment requests and receiving reports, as authorized by DFARS 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.
- (c) WAWF access. To access WAWF, the Recipient shall (i) have a designated electronic business point of contact in the System for Award Management at https://www.acquisition.gov; and (ii) be registered to use WAWF at https://wawf.eb mil/ following the step-by-step procedures for self-registration available at this website.
- (d) WAWF training. The Recipient should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the "Web Based Training" link on the WAWF home page at https://wawf.eb mil/.
- (e) WAWF methods of document submission. Document submissions may be via Web entry, Electronic Data Interchange, or File Transfer Protocol.
- (f) WAWF payment instructions. The Recipient must use the following information when submitting payment requests and receiving reports in WAWF for this contract/order:
 - (1) Document type. The Recipient shall use the following document type: Invoice and Receiving Report (Combo)
 - (2) Inspection/acceptance location. The Recipient shall select the following inspection/acceptance location(s) in WAWF, as specified by the contracting officer.
 - (3) Document routing. The Recipient shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.

Routing Data Table*

Field Name in WAWF	Data to be entered in WA		
Pay Official DoDAAC	HQ0337		
Issue By DoDAAC	W911SR		
Admin DoDAAC	S3101A		
Inspect By DoDAAC	W56XNH		
Ship To Code	W56XNH		

Payee Information: As identified at the System for Award Management.


Becton, Dickinson and Company

Cage Code: 06531DUNS: 001292192

- (4) Payment request and supporting documentation. The Recipient shall ensure a payment request includes appropriate contract line item and subline item descriptions of the work performed or supplies delivered, unit price/cost per unit, fee (if applicable), and all relevant back-up documentation in support of each payment request.
- (5) WAWF email notifications. The Recipient shall enter the email address identified below in the "Send Additional Email Notifications" field of WAWF once a document is submitted in the system.

(g) WAWF point of contact.

 The Recipient may obtain clarification regarding invoicing in WAWF from the following contracting activity's WAWF point of contact.



(2) For technical WAWF help, contact the WAWF helpdesk at 866-618-5988.

6. Accounting & Audit

6.1 Accounting System.

- 6.1.1. The Recipient's cost accounting system shall be in compliance with Generally Accepted Accounting Principles (GAAP) in accordance with 32 CFR §37.615. The system must effectively control all Project funds, including Federal funds and any required cost share. The system must have complete, accurate, and current records that document the sources of funds and the purposes for which they are disbursed. It also must have procedures for ensuring that Project funds are used only for purposes permitted by the agreement (§ 37.625).
- 6.2 Annual Audit Requirement. The Recipient shall have an annual audit performed by an independent auditor, in accordance with 32 CFR §37.650. The Recipient shall provide a copy of the auditor's report to the Agreements Officer within 60 days after audit. Audits at Appendix C of 32 CFR Part 37 is incorporated into this Agreement.
- 6.3 Program Income. Program income derived during the initial Period of Performance from Government funding shall be allocated to finance the non-Federal share of the Project (including the amounts described in Section 8.1) in accordance with 32 CFR §34.14(d)(2). As contemplated by 32 CFR §34.14(b)(2), Recipient will have no obligation to the Government for program income generated after the end of the Period of Performance, and no recovery of funds is contemplated under 32 CFR §37.580. With the exception of the reimbursements contemplated in Paragraph 9.1, Paragraph 6.3 shall not require the Recipient to provide to the Government any income received from sales of Qualifying Product (as defined below), nor shall it alter the overall cost sharing arrangement in Section [6].

7. Purchasing & Title

7.1 Title to Property Acquired under Agreement. Title to real property, equipment, and supplies or intangible property that are acquired by the Recipient (whether by purchase, construction or fabrication, development, or otherwise) with Government funding vests in the Recipient conditionally as described at 32 CFR 37.685.

- 7.1.1 Equipment Costs. Pursuant to 32 CFR 37.685 (b)(2), the Recipient is authorized to include the full acquisition cost of equipment as part of the cost of the project.
- 7.1.2 Property Management. Real property and equipment acquired by the Recipient during the Agreement is subject to the property management standards in 32 CFR 34.21(b) through (d).
- 7.2 Disposition. Any Federal interest in the real property or equipment remaining after the term will be addressed at the time of property disposition. Disposition will be in accordance with 32 CFR 34.21.
- 7.3 Purchasing System. If the Recipient currently performs under DoD assistance instruments subject to the purchasing standards in 32 CFR 34.31, then that Part applies. Otherwise, the Recipient may use the existing purchasing systems, as long as applicable requirements are flowed down (37.705).

8. Cost Sharing

- 8.1 To the maximum extent practicable, the recipient must provide at least half of the costs of the project, in accordance with § 37.215. *Total value* of the TIA means the total amount of costs that are currently expected to be charged to the award over its life, which includes amounts for the Federal share and any non-Federal cost sharing or matching required under the award; and any options, even if not yet exercised, for which the costs have been established in the award.
- 8.2 Notwithstanding 8.1 to the contrary, the Government funding is estimated to represent approximately 60% of the overall amount necessary to accomplish the scope of work cited in the proposal (inclusive of all proposal revisions and appendices). The Recipient agrees to provide the resources in the manner shown in their proposal.
- 8.3 Failure of either Party to provide its respective total contribution may result in a unilateral modification to this Agreement by the AO to reflect proportional reduction in funding for the other Party.

9. Government Preference

- 9.1 Pricing. During the term of the Agreement, the Recipient agrees that, in the event that it enters into a Group Purchasing Organization (GPO) contract with a Qualifying Third Party (as defined below) with respect to a Qualifying Product (as defined below) with a per unit GPO price lower than that offered for the same Qualifying Product to the Government, the Recipient shall (i) promptly notify the Agreements Officer in writing of the lower price and (ii) extend the lower price to all future sales of the Qualifying Product to the Government. For any purchases that were made after the lower price was first extended to the Qualifying Third Party, the Recipient shall reimburse the Government, the difference between the lower price provided to the Qualifying Third Party and the price provided to the Government, multiplied by the volume/quantity provided after the lower price was first extended. Such reimbursement shall occur within thirty days (30) of the Recipient discovering that the lower price was given to the Qualifying Third Party. Notwithstanding the foregoing, the Parties may agree to apply the reimbursement toward additional quantities/volume of Qualifying Product required by the Government. For the purposes of this Article, (a) "Group Purchasing Organization (GPO)" means an entity that aggregates purchasing volume of healthcare item(s) to realize savings and efficiencies (b) "Qualifying Third Party" means the national GPO in the United States that represents the largest volume of total dollar sales of Qualifying Products in the aggregate with Recipient, as determined on an annual basis by Recipient, and communicated to the Agreements Officer and (c) a "Qualifying Product" is a syringe or needle manufactured, in whole or in part, utilizing equipment funded under this Agreement.
- 9.2 Precedence. During the period of performance and upon a Presidential Declaration of a Public Health Emergency (a "PHE"), Recipient shall grant the Government the right to place Priority Orders for Qualifying Product so long as the Qualifying Product is intended for use to address the PHE. For purposes of this Section, (a) "Priority Orders" shall mean purchase orders for Qualifying Product that will be prioritized by Recipient as if they were "rated orders" subject to 15 CFR § 700.14.
- 9.3 Maintenance of equipment and availability of capacity. Recipient agrees that, for the term of this Agreement, it shall maintain all equipment funded by the Agreement in such a way as to ensure that, should the rights established

under 9.2 be in effect, there is capacity equal to that which was available at time of commissioning. Further, the Recipient agrees that should the equipment funded by this agreement be unavailable during a period in which the rights under 9.2 are in effect, the Recipient will make available to the Government equivalent capacity from any existing US-based equipment not funded under this agreement capable of producing Qualifying Product.

9.4. Inspection of equipment. The Recipient grants the Government the right to inspect at any time, upon provision of reasonable advance notice, the equipment funded by this agreement.

10. Records Retention & Government Access

The DoD, Comptroller General of the United States, or any of their duly authorized representatives, have the right of timely and unrestricted access to any books, documents, papers, or other records of the Recipient that are pertinent solely to the Recipient's technical performance under this Agreement, in order to make examinations, excerpts, transcripts and copies of such documents. This right also includes timely and reasonable access to the Recipient's personnel for the purpose of interview and discussion related to such records. Such access shall be performed during business hours on business days upon written notice and shall be subject to the security requirements of the audited Party to the extent such security requirements do not conflict with the rights of access otherwise granted by this paragraph. The rights of access in this paragraph shall last as long as records are retained. The rights of access in this paragraph do not extend to the Recipient's financial records.

- 11. Intellectual Property & Patent Rights. Reserved; the Government does not anticipate any intellectual property being generated under this Agreement.
- 12. Data Rights. The Government may only request technical data that is customarily provided to the public with a commercial item or process related to for Qualifying Products, equipment purchased under this Agreement, and repairs or maintenance to said equipment.

13. U.S Food and Drug Administration (FDA) Regulatory Compliance

- 13.1 Good Manufacturing Practices (GMP) Compliance. To the extent required under the Federal Food, Drug, and Cosmetic Act, the Recipient will ensure that the manufacturing capability established under this Agreement complies with current good manufacturing practices (cGMPs) under 21 CFR 210 and 211. The Recipient will notify the Government of any written cGMP inspection findings from the FDA pertinent to the manufacturing capability established under this Agreement.
- 13.2 FDA Communications. The Recipient will provide the Government with summaries of any Recipient formal meetings with the FDA and future correspondence between Recipient and the FDA regarding the manufacturing contemplated under this Agreement and ensure that Government representatives are invited to participate in any Recipient formal meetings with the FDA regarding topics that are material to Recipient's compliance with the terms of this Agreement.

14. Termination

Termination and Enforcement procedures are in accordance with 32 CFR §34.51 through §34.52.

15. Disputes

For any disagreement, claim, or dispute arising under this Agreement, the parties shall communicate with one another in good faith and in a timely and cooperative manner. Whenever disputes, disagreements, or misunderstandings arise, the parties shall attempt to resolve the issue by discussion and mutual agreement as soon as practicable. Failing resolution by mutual agreement, the aggrieved party shall request a resolution in writing from the AO. The AO will review the matter and render a decision in writing. Any such decision is final and binding. In the event of a decision, within 60-calendar days of the referral for review (or such other period as agreed upon by the parties), either party may pursue any right or remedy provided by law in a court of competent jurisdiction as authorized by 28 U.S.C. 1491. Alternately, the parties may agree to explore and establish and Alternate Disputes Resolution procedure to resolve this dispute.

16. Reports & Distribution

- 16.1 Monthly Progress Reports. Submitted monthly no later than the 10th of the month. Recipient format acceptable. Electronic submission acceptable in MS Office or PDF format. Financial information shall be MS Excel format. Monthly reports shall have Distribution Statement C (U.S. Government and their contractors). Each monthly report shall, at a minimum, contain the following:
 - a. Summary of monthly progress for the Recipient's facilities/capabilities associated with this effort
 - b. Summary of progress towards established milestones for each facility/capability
 - Identification of any milestone that is slipping or missed, and discussion of path forward to bring milestone back to schedule, and impact on other milestones
 - d. Summary of risks, discussion of potential impacts and efforts to mitigate
 - e. Summary of overall schedule and changes from previous month
 - f. Financial summary of Recipient costs incurred by month to date, vouchers submitted, and Government payments made
- 16.2 Quarterly-In-Process Reviews. Scheduled as needed, generally not more frequently than quarterly, at the Recipient's facilities. Duration: eight (8) hours max. Face-to-face or virtual review of previous quarter's activities. Informative in nature to keep BARDA apprised of project progress and to discuss issues that may require joint resolution, such as milestone changes, political impacts on objectives, schedule, funding.
- 16.3 Annual Financial Status Report. (37.880)
- 16.4 Final Report. Final Report shall have Distribution Statement C. Final report summarizing stated objectives and the progress that was achieved in meeting those objectives; summary of risks incurred, impacts and mitigation; quantitative discussion of needle & syringe production throughput improvements achieved; financial summary of project; schedule summary for project, comparing original schedule to final schedule; recommendations for path forward as applicable.

17. Modification of the Agreement

- 17.1 Limitation. In no event shall any understanding or agreement, modification, change order, or other matter in deviation from the terms of this agreement between the Recipient and a person other than the AO be effective or binding upon the Government. All such actions must be formalized by a proper contractual document executed by the AO. The only method by which this Agreement can be modified is by a formal, written modification signed by the AO. No other communications, whether oral or in writing, shall modify this Agreement.
- 17.2 Recommendation. Modifications to this Agreement may be proposed by either Party. Recipient recommendations for any modifications to this Agreement, including justifications to support any changes to the proposal (inclusive of proposal revisions, proposal appendices, and the collaboration plan), as incorporated by reference, shall be submitted in writing to the Government PM with a copy to the AO. The Recipient shall detail the technical, chronological, and financial impact of the proposed modification to the program. Changes are effective only after this Agreement has been modified. The AO is responsible for the review and verification of any recommendations.
- 17.3 Unilateral or Minor. The AO may unilaterally issue administrative Agreement modifications (e.g., changes in the paying office or appropriation data, or changes to Government personnel identified in this Agreement, etc.). All other modifications shall be the result of bilateral agreement of the Parties. The Government may make minor or administrative Agreement modifications unilaterally.

18. Miscellaneous

- 18.1 Security. The Recipient shall not develop and/or handle classified information in the performance of this Agreement. No DD254 is currently required for this Agreement.
- 18. 2 Entire Agreement. This Agreement, inclusive of the proposal, proposal revision, proposal appendices, and collaboration plan(s), constitutes the entire Agreement between the Parties concerning the subject matter hereof and

supersedes any prior understandings or written or oral Agreement relative to said matter. In the event of a conflict between the terms of this Agreement, the terms of this Agreement shall govern.

- 18.3 Waiver of Rights. Any waiver of any requirement contained in this Agreement shall be by mutual agreement of the Parties hereto. Any waiver shall be reduced to a signed writing and a copy of the waiver shall be provided to each Party. Failure to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, shall not be deemed a waiver of any rights of any Party hereto.
- 18.4 Liability. No Party to this Agreement shall be liable to the other Party for any property consumed, damaged, or destroyed in the performance of this Agreement, unless it is due to the negligence or willful misconduct of the Party or an employee or agent of the Party. In no event shall either Party be liable for special, incidental, or consequential damages arising from or connected with this Agreement.
- 18.5 Non-Assignment. This Agreement may not be assigned by any Party except by operation of law resulting from the merger of a Party into or with another corporate entity.
- 18.6 Severability. If any clause, provision or section of this Agreement shall be held illegal or invalid by any court, the invalidity of such clause, provision, or section shall not affect any of the remaining clauses, provisions, or sections herein, and this Agreement shall be construed and enforced as if such illegal or invalid clause, provision, or section had not been contained herein.
- 18.7 Force Majeure. Neither Party shall be in breach of this Agreement for any failure of performance caused by any event beyond its reasonable control and not caused by the fault or negligence of that Party. If such a force majeure event occurs, the Party unable to perform shall promptly notify the other Party and shall in good faith maintain such partial performance as is reasonably possible and shall resume full performance as soon as is reasonably possible.
- 18.8 Foreign Access to Technology & Domestic Manufacturing.
- 18.8.1 Activities Abroad. The Recipient shall assure that project activities carried on outside the United States are coordinated as necessary with appropriate Government authorities and that appropriate licenses, permits, or approvals are obtained prior to undertaking proposed activities. The awarding agency does not assume responsibility for Recipient compliance with the laws and regulations of the country in which the activities are to be conducted.
- 18.8.2 Export. The Parties understand that information and materials provided pursuant to or resulting from this Agreement may be export controlled, sensitive, for official use only, or otherwise protected by law, executive order, or regulation. The Recipient is responsible for compliance with all applicable laws and regulations. Nothing in this Agreement shall be construed to permit any disclosure in violation of those restrictions.
- 18.8.3. Exclusive right to use technology in the United States must, unless the Government grants a waiver, require that products embodying the technology or produced through the use of the technology will be manufactured substantially in the United States (37.875).

IN WITNESS WHEREOF, each Party has executed this Agreement by signature of its authorized representative.

SIGNATURES: Recipient (b) (6)	Government (b) (6) (b) (2)
Signature	Signature (b) (6)
(b) (6)	Printed Name Agreements Officer
Title 7/1/2020	Title
Date	Date